Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Double-Blind, Placebo-Controlled, Two-Part Study (Part 1 Open-Label) to Assess the Safety, Efficacy and Pharmacokinetics of Single Intravenous Doses of ASP8597 (Diannexin) in de Novo Kidney Transplant Recipients

NCT01442337 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT01442337
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01442337 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Double-Blind, Placebo-Controlled, Two-Part Study (Part 1 Open-Label) to Assess the Safety, Efficacy and Pharmacokinetics of Single Intravenous Doses of ASP8597 (Diannexin) in de Novo Kidney Transplant Recipients
Lead sponsor
Astellas Pharma Inc
Phase
Phase 2/3
Overall status
Terminated
Start date
December 31, 2011
Completion date
July 31, 2013
Enrollment
21 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplantation